Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amarin's Omega-3 Fair Trade Complaint Questions US Dietary Ingredient Standards

Executive Summary

Amarin's recent fair trade complaint targetting purified EPA dietary supplements and formulations also raises broader questions about using synthetic dietary ingredients in consumer supplements and the extent to which a substance’s identification in an IND precludes subsequent use as a dietary ingredient.


Related Content

Omega-3 Ingredients Fair Trade Complaint? Not FDA's Bailiwick, Amarin Says
Fair Trade Is Not FDA's Expertise, Amarin Says In Omega-3 Ingredients Filing
FDA Objects To Amarin Trade Complaint Against Omega-3 Ingredients
Amarin Seeks ITC Action Against Products 'Cloaked' As Dietary Supplements
‘Old’ Ingredient List On FDA Table Could Spur New Supplement Launches
Herbal Sleep Aid With Rx 'Reformulation' Gives FDA A Nightmare
Hatch Questions FDA Motive, Process In Proposed Vinpocetine Ban
FDA Finds Ingredient's IND Past After Signing Off For Supplement Use
FDA's Initial IND Warnings For CBD Supplements Could Ignite Regulatory Test
Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts